Pneumococcal Pneumonia Clinical Trial
Official title:
Immunogenicity and Reactogenicity of 10-valent Pneumococcal Conjugate Vaccine (PCV10) in Children Aged 12-59 Months
The World Health Organization has recommended that developing countries should incorporate pneumococcal conjugate vaccine (PCV) into their routine immunization schedules. The Kenya Ministry of Health anticipates introducing a new formulation of PCV, PCV10, into the routine childhood immunization schedule in 2010. In the areas of Kenya that have been designated to monitor the impact of vaccine, a catch-up campaign will be implemented to vaccinate children aged 12-59 months. PCV10 has been found to be safe and effective in infants. It is licensed for use in children up to 2 years of age, but its use as a primary series in children over age 12 months has not been evaluated. This study will assess the immunogenicity and reactogenicity of PCV10 first administered at an age of 12-59 months.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03303976 -
Phase I to Test a New Pneumococcal Vaccine
|
Phase 1 | |
| Completed |
NCT02592486 -
The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine
|
Phase 4 | |
| Completed |
NCT03851978 -
Pharmacist Impact on Pneumococcal Polysaccharide Vaccination Rates in Patients With Diabetes in a Supermarket Pharmacy Chain
|
N/A | |
| Completed |
NCT01444352 -
Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults
|
Phase 1 | |
| Completed |
NCT03619252 -
Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
|
Phase 4 | |
| Completed |
NCT01402245 -
Targeting of Immune Response After Pneumococcal Vaccination
|
Phase 4 | |
| Completed |
NCT01444339 -
Study of Two Investigational Pneumococcal Vaccines in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01444001 -
Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers
|
Phase 1 |